- Home
- MODD vs KYNB Comparison
MODD vs KYNB Comparison
Compare MODD & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | KYNB |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 27.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MODD | KYNB |
|---|---|---|
| Price | $4.63 | $7.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 120.9K | 37.3K |
| Earning Date | 02-17-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $6.32 |
| 52 Week High | $6.16 | $9.58 |
Technical Indicators
Market Signals| Indicator | MODD | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 63.00 |
| Support Level | $3.92 | $6.59 |
| Resistance Level | $5.80 | $7.95 |
| Average True Range (ATR) | 0.81 | 0.32 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 28.74 | 72.73 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.